12/30/2004

Although 2004 is replete with "blowups" of biotechnology companies, the sector is entering 2005 with good momentum, the most heavily capitalized staying stronger than small-cap firms, according to a senior writer at TheStreet.com. U.S. cutbacks in Medicare reimbursements next year could lead to a trend change in drug usage and affect biotech companies such as Amgen, Genentech and Biogen Idec.

Full Story:
TheStreet.com

Related Summaries